The Limited Times

Now you can see non-English news...

Covid: Valneva's obstacle course


ANALYSIS – The Franco-Austrian biotech has received a notice of termination from Brussels. The agreement is for 60 million doses.

The battle against the Covid is a journey strewn with pitfalls for Valneva.

The Franco-Austrian biotech warned on Monday that the European Commission intended to terminate the agreement to supply 60 million doses of its Covid vaccine (including 24.3 million delivered this year).

An announcement that caused a fall of nearly 20% of the Valneva title, to 9.64 euros.


The European Commission's decision is regrettable, especially as we continue to receive messages from Europeans seeking a more traditional vaccine solution,

" said Thomas Lingelbach, CEO of Valneva.

Valneva continues to believe that its vaccine candidate can still make an important contribution to the fight against Covid-19 and complement existing vaccines with a whole virus inactivated approach.


To discover

  • Taxes 2022: all about your tax return

Read also

Germany: surge in anti-Semitism under the effect of the Covid

The contract between Brussels and Valneva, which had been signed after long weeks of negotiations, authorized the Commission to terminate it...

This article is for subscribers only.

You have 74% left to discover.

Cultivating your freedom is cultivating your curiosity.

Keep reading your article for 1€ the first month


Already subscribed?


Source: lefigaro

All business articles on 2022-05-16

You may like

Trends 24h

Business 2022-07-04T02:34:21.591Z


© Communities 2019 - Privacy